TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA). Issue 10 (10th October 2022)

• Record Type: Journal Article
• Authors: Kleinrensink, Nienke J; Perton, Frank T; Pouw, Juliëtte N; Vincken, Nanette L A; Hartgring, Sarita A Y; Jansen, Mylène P; Arbabi, Saeed; Foppen, Wouter; de Jong, Pim A; Tekstra, Janneke; Leijten, Emmerik F A; Spierings, Julia; Lafeber, Floris P J G; Welsing, Paco M J; Heijstek, Marloes W
• Is Part Of: BMJ open. Volume 12:Issue 10(2022)
• Publication Date: 2022-10-10
• Subjects: rheumatology -- immunology -- Magnetic Resonance Imaging; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2022-064338
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Psoriatic arthritis (PsA) is a chronic, inflammatory, musculoskeletal disease that affects up to 30% of patients with psoriasis. Current challenges in clinical care and research include personalised treatment, understanding the divergence of therapy response and unravelling the multifactorial pathophysiology of this complex disease. Moreover, there is an urgent clinical need to predict, assess and understand the cellular and molecular pathways underlying the response to disease-modifying antirheumatic drugs (DMARDs). The TOFA-PREDICT clinical trial addresses this need. Our primary objective is to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in PsA. Methods and analysis: In this investigator-initiated, phase III, multicentre, open-label, four-arm randomised controlled trial, we plan to integrate clinical, molecular and imaging parameters of 160 patients with PsA. DMARD-naïve patients are randomised to methotrexate or tofacitinib. Additionally, patients who are non-responsive to conventional synthetic (cs)DMARDs continue their current csDMARD and are randomised to etanercept or tofacitinib. This results in four arms each with 40 patients. Patients are followed for 1 year. Treatment response is defined as minimal disease activity at week 16. Clinical data, biosamples and images are collected at baseline, 4 weeks and 16 weeks; at treatment failure (treatment switch) and 52 weeks. For the first 80 patients, we will use a systems medicine approach to assess multiomics biomarkers and develop a prediction model for treatment response. Subsequently, data from the second 80 patients will be used for validation. Ethics and dissemination: The study was approved by the Medical Research Ethics Committee in Utrecht, Netherlands, is registered in the European Clinical Trials Database and is carried out in accordance with the Declaration of Helsinki. The study's progress is monitored by Julius Clinical, a science-driven contract research organisation. Trial registration number: EudraCT: 2017-003900-28.